KETTERING, Ohio (WDTN) – Kettering Medical Center is participating in an expanded access clinical trial for the antiviral drug remdesivir, which has shown in preliminary trials to help COVID-19 patients recover more quickly.
The announcement was made in a release Thursday. Other Kettering Health Network hospitals caring for COVID-19 patients are in the process of applying for acceptance into the trial.
Gilead Sciences, the maker of remdesivir, reported Wednesday preliminary results of a randomized trial showed earlier recovery in patients treated with the antiviral drug compared to a placebo-recovery time was an average of 11 days versus 15 days, an improvement of 31 percent, according to KHN.
“We are thrilled to be part of this groundbreaking clinical trial,” says Dr. Patrick Lytle, vice president of Clinical Outcomes for Kettering Health Network. “Initial results are very promising, and with more testing, we can further determine remdesivir’s safety and effectiveness.”
- Oklahoma mom warns of the dangers of open-air carbon monoxide poisoning after her son dies after a day on the lake
- 84-year-old man taking photos of boys outside Missouri grade school charged with child porn
- Cancer medications in short supply as hospitals battle COVID-19 south of the border
- President Trump expected to nominate Amy Coney Barrett to Supreme Court
- HHS secretary touts Trump’s health care plan while Democrats say there’s nothing in it